Liquidia (NASDAQ:LQDA - Get Free Report) had its price target increased by investment analysts at Scotiabank from $30.00 to $34.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "sector outperform" rating on the stock. Scotiabank's target price would indicate a potential upside of 121.79% from the stock's previous close.
LQDA has been the topic of several other research reports. Needham & Company LLC boosted their price target on Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They set an "overweight" rating and a $20.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $26.63.
Read Our Latest Stock Report on LQDA
Liquidia Trading Up 1.4 %
Shares of LQDA traded up $0.21 during midday trading on Thursday, hitting $15.33. 262,728 shares of the company's stock traded hands, compared to its average volume of 931,886. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92. The firm's fifty day moving average is $14.79 and its 200-day moving average is $12.23. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.40 and a beta of 0.07.
Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, equities research analysts anticipate that Liquidia will post -1.51 EPS for the current year.
Insider Buying and Selling
In related news, General Counsel Russell Schundler sold 16,393 shares of the business's stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,445 shares of the firm's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock worth $843,326 in the last 90 days. Insiders own 30.10% of the company's stock.
Institutional Investors Weigh In On Liquidia
A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Liquidia by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock valued at $41,834,000 after purchasing an additional 115,367 shares in the last quarter. LM Advisors LLC acquired a new stake in Liquidia during the fourth quarter worth about $25,948,000. Whitefort Capital Management LP raised its stake in Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock worth $23,370,000 after purchasing an additional 285,220 shares during the period. Vestal Point Capital LP boosted its holdings in Liquidia by 17.3% in the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock valued at $20,698,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Liquidia by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after buying an additional 101,597 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Read More
Before you consider Liquidia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.
While Liquidia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
